Low-Dose Naltrexone and Gabapentin Interaction: What Patients and Clinicians Need to Know

Low-dose naltrexone (LDN) is a compounded, off-label preparation of naltrexone, an opioid receptor antagonist FDA-approved at full dose (50 mg, brand names Revia and, as an extended-release injection, Vivitrol) for alcohol and opioid use disorder. At LDN doses of roughly 1.5 to 4.5 mg nightly, it is used off-label for conditions such as fibromyalgia and some autoimmune diseases, with no FDA-approved indication or dedicated FDA label at this dose range. Gabapentin (brand name Neurontin, also available generically and as the related extended-release product Horizant) is a gabapentinoid FDA-approved for partial seizures and postherpetic neuralgia, and used off-label at various doses for neuropathic pain and other conditions.

No dedicated pharmacokinetic or clinical interaction trial of LDN combined with gabapentin was located for this article. The guidance below is extrapolated from each drug's individual FDA labeling, general pharmacology, and evidence from separate studies of each agent. Treat every claim here as an extrapolation unless stated otherwise, and confirm specifics with a pharmacist or prescriber before relying on them for an individual patient.

Naltrexone and gabapentin do not share a metabolic pathway that would produce a classic pharmacokinetic drug interaction. Gabapentin is excreted unchanged by the kidneys and is not metabolized by cytochrome P450 enzymes; naltrexone is metabolized mainly by cytosolic carbonyl reductase to 6-beta-naltrexol, not by CYP3A4 or CYP2D6. The clinically relevant concern is pharmacodynamic: both drugs can cause central nervous system depression, and gabapentin's FDA label carries a warning about respiratory depression when combined with other CNS depressants, a risk that rises with gabapentin dose and with reduced kidney function.

What is established, what is plausible, and what is not established

Established: Gabapentin is renally cleared and its FDA label specifies dose reductions at reduced creatinine clearance; the FDA issued a 2019 drug safety communication warning that gabapentin, "in combination with CNS depressants," carries a risk of serious breathing difficulties, particularly in patients with respiratory risk factors as described in an FDA drug safety communication. Naltrexone's full-dose label describes carbonyl-reductase metabolism and renal excretion of its active metabolite, with severe renal impairment listed as a caution as described in naltrexone's FDA prescribing information.

Plausible but unproven at LDN doses: That LDN's transient (roughly 4 to 6 hour) mu-opioid blockade meaningfully adds to gabapentin-related sedation is biologically plausible given that both drugs act on overlapping CNS circuits, but no trial has measured this additive effect directly. A small crossover trial of LDN 4.5 mg alone in fibromyalgia found a side-effect profile dominated by vivid dreams and transient insomnia rather than sedation, which suggests LDN's own sedative contribution at this dose is modest, though this trial did not test gabapentin co-administration (Younger et al., 2013).

Not established: Any specific quantified increase in sedation, fall risk, or respiratory depression when LDN and gabapentin are combined, as distinct from gabapentin alone. Standard drug interaction databases (Lexicomp, Micromedex, and similar tools) generally classify this pairing as a moderate interaction based on additive CNS depression rather than a documented pharmacokinetic mechanism, but database classification is not the same as trial evidence.

Requires verification before clinical use: Any exact percentage, prescribing-frequency statistic, or guideline quotation about this specific combination should be checked against the primary source before being used in a chart note or patient handout. Several figures that circulated in earlier drafts of this topic (a specific overdose-death percentage, a specific systematic-review trial count, a specific case series of combined use) could not be confirmed against the citations available for this article and have been removed or narrowed below.

Why the interaction is not CYP-mediated

Gabapentin is absorbed via the L-amino acid transporter system in the small intestine, circulates largely unbound, and is eliminated unchanged in the urine; it does not undergo hepatic metabolism. Naltrexone's active metabolite, 6-beta-naltrexol, is produced by cytosolic carbonyl reductase, not by cytochrome P450 enzymes, according to its FDA label according to naltrexone's FDA prescribing information. Because neither drug induces or inhibits hepatic enzymes in a clinically meaningful way, standard interaction checkers correctly flag this pair as pharmacokinetically low-risk. That does not mean the combination is risk-free; it means the risk sits elsewhere.

Where the real risk sits: additive CNS depression and renal clearance

Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels and reduces neuronal excitability, producing dose-dependent sedation and, per the FDA's 2019 communication, a respiratory depression risk that is more pronounced with concurrent CNS depressants, in older adults, and in patients with existing respiratory impairment. LDN's transient mu-opioid blockade is not, by itself, a strong CNS depressant at 1.5 to 4.5 mg, but the combination still adds one more CNS-active agent to a regimen where gabapentin dose and renal function already matter.

Both drugs rely heavily on renal excretion. The FDA gabapentin label specifies dose ceilings tied to creatinine clearance (for example, no more than 1,400 mg/day divided across two doses at creatinine clearance 30 to 59 mL/min, dropping further as clearance declines) according to gabapentin's FDA prescribing information. Roughly 38% of an oral naltrexone dose is excreted as 6-beta-naltrexol within 24 hours per the same class of labeling, and severe renal impairment is listed as a caution for full-dose naltrexone. At LDN doses, the naltrexone renal load is a small fraction of the 50 mg label dose, so the practical concern is less "does LDN accumulate" and more "does reduced kidney function let gabapentin accumulate while a second CNS-active drug is also present."

A reasonable practical threshold: an eGFR below 60 mL/min (CKD stage 3a or lower) should prompt a gabapentin dose review at or before the time LDN is introduced, since a patient on high-dose gabapentin with reduced clearance is a materially different risk case than a patient on a low gabapentin dose with normal renal function.

Evidence-status interaction assessment

This table separates what current sources support from what is extrapolated, so a clinician or pharmacist can see exactly where the evidence ends and judgment begins.

What the individual-drug evidence shows

LDN's own adverse-effect profile

The best-known controlled trial of LDN in fibromyalgia is a small (N=31), randomized, double-blind, placebo-controlled crossover study by Younger and colleagues, which reported reduced pain scores with LDN 4.5 mg versus placebo and described side effects as mostly vivid dreams and transient insomnia in the first week, without sedation as a dominant complaint (Younger et al., 2013). A single small trial in one condition (fibromyalgia) is not proof that LDN is sedation-free in all patients or in combination with other drugs, but it is the most direct evidence available on LDN's own tolerability signature. A separate narrative review of LDN as an anti-inflammatory agent discusses its general adverse-effect pattern, including sleep disturbance and gastrointestinal upset, without providing the specific "15 trials, 30% incidence" figure sometimes attributed to this literature; that more precise figure could not be confirmed and should be verified against a primary systematic review before being used clinically (Younger, Parkitny, McLain, 2014).

Gabapentin's own risk profile

A systematic review of gabapentin misuse, abuse, and diversion documents that gabapentin is increasingly implicated in polysubstance overdose contexts, particularly alongside opioids, and discusses CNS depression as a mechanism, without establishing a precise standalone percentage for any single cohort in the material available here (Smith, Havens, Walsh, 2016). The FDA's own 2019 communication is the more authoritative and dated source for the respiratory depression warning and should be cited directly for that claim rather than a secondary review as described directly in the FDA's 2019 drug safety communication.

Mechanistic background

Naltrexone's transient mu-opioid blockade at LDN doses, followed by receptor upregulation, is proposed to reduce microglial activation via TLR4 signaling and modulate inflammatory cytokine release; a small pilot study reported lower markers of central sensitization in fibromyalgia patients on LDN compared with placebo (Younger & Mackey, 2009). This is mechanistic and pilot-level evidence, not confirmation of a specific interaction with gabapentin. A broader review of LDN's therapeutic uses across conditions provides useful background on dosing and general tolerability but does not describe a controlled case series combining LDN with gabapentin; an earlier version of this article referenced a "2020 case series (N=12)" for that combination, and that description could not be verified against the source available and has been removed (Toljan & Vrooman, 2018).

Practical risk stratification

Not every patient combining LDN and gabapentin faces the same risk. The tiers below are a HealthRX.com-drafted clinical framework based on the pharmacology and label data above, intended as a starting point for clinician judgment rather than a validated risk calculator.

Monitoring before and after starting the combination

Before starting LDN in a patient already on gabapentin:

• Basic metabolic panel with eGFR and serum creatinine
• Current gabapentin dose, dosing frequency, and indication
• A full list of concurrent CNS depressants: benzodiazepines, opioids, muscle relaxants, sedating antihistamines, alcohol use
• A fall-risk assessment, particularly for patients 65 or older

After starting:

• Ask specifically about morning sedation, dizziness on standing, and any confusion at follow-up, rather than a general "how are you feeling"
• Recheck eGFR at 8 to 12 weeks if baseline eGFR was between 45 and 60 mL/min
• If eGFR falls below 45, review the FDA gabapentin dose-reduction table before continuing LDN

Patient counseling points:

1. Do not add any new sedating medication, including over-the-counter diphenhydramine or doxylamine, without telling the prescriber.
2. Avoid alcohol during titration of either drug; alcohol compounds gabapentin sedation and carries a separate caution with naltrexone.
3. LDN is typically taken at bedtime. If gabapentin is also dosed only at night, both drugs reach peak plasma levels around the same time; for patients on higher total daily gabapentin doses, redistributing some of the dose earlier in the day (discussed with the prescriber, not self-adjusted) may reduce overnight sedation overlap.

Special populations

Older adults. Age-related decline in eGFR means gabapentin can accumulate even when serum creatinine looks normal. The American Geriatrics Society's 2023 Beers Criteria update lists gabapentinoids as potentially inappropriate in older adults because of CNS and fall risk, especially combined with other CNS-active agents (Beers Criteria, 2023). LDN is not on the Beers list, but adding it to an older adult's gabapentin regimen is a reasonable trigger for pharmacist review.

Fibromyalgia and central sensitization syndromes. This is the population most likely to be prescribed both drugs, since gabapentin (and pregabalin) have FDA-approved or well-established off-label roles in fibromyalgia, and LDN has off-label trial evidence in the same condition. That the two are sometimes prescribed together for a shared indication does not reduce the monitoring described above.

Multiple sclerosis and other neuropathic pain conditions where LDN is used off-label. A systematic review of pain prevalence in MS confirms that neuropathic pain is common in this population, but does not itself establish how often gabapentinoids specifically are prescribed relative to other agents; that prescribing-frequency claim should be sourced separately if needed (Foley et al., 2013).

When the combination should not be started, or should be stopped, without specialist input

• Concurrent opioid analgesic use. Naltrexone at any dose can precipitate opioid withdrawal, and adding gabapentin on top of that scenario creates a three-way CNS risk that needs specialist coordination.
• Scheduled (not occasional) benzodiazepine use, given the well-recognized risk of combining CNS depressants with opioid-system-active drugs and gabapentinoids.
• eGFR below 15 mL/min, where both drugs require adjusted or avoided dosing.
• Active, ongoing heavy alcohol use, which can affect liver enzymes with naltrexone and sharply increases gabapentin sedation.

None of these is unique to LDN specifically; they reflect general CNS-depressant and renal-clearance principles that apply whenever gabapentin is combined with another centrally active drug.

When to seek urgent care

If you experience persistent unusual drowsiness, slowed or shallow breathing, confusion, or difficulty being awakened while taking low-dose naltrexone with other medications, contact your healthcare provider urgently rather than scheduling a routine appointment.